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CELL-MEDIATED IMMUNOTHERAPY: ITS ROLE IN CANCER 
TREATMENT 
JANHAVEE DESHPANDE 
ABSTRACT 
  
Cancer is the second most common cause of death in the United States behind 
heart disease. While current treatments such as surgery, chemotherapy, and radiation 
therapy are effective and widely used, medicine is moving towards more targeted and 
personalized therapies. Immunotherapy is one such treatment that utilizes the patient’s 
own immune system to target and eliminate tumor cells. It allows for the patient’s 
adaptive immune system to bypass the self-tolerance mechanisms used by the cancerous 
cells and be activated against the cancer. Two such self-tolerant mechanisms that are co-
opted by tumor cells are the interactions between CTLA-4 and T lymphocytes and the 
interactions between PD-1 and PD-L1. Blocking these interactions allows for the 
recruitment of CTLs to the site of the tumor and subsequent attack. CTLA-4 and PD-1 
are inhibitory costimulators that play a role in the suppression of the adaptive immune 
system. The interaction of these receptors with their respective ligands leads to self-
tolerance, and is a common mechanism used as a protective measure against autoimmune 
reactions.  
Monoclonal antibodies against these two receptors and ligand have been tested in 
clinical trials and have shown efficacy against ovarian cancers, non-small cell lung 
carcinomas, colon cancers, and melanomas. By targeting the inhibitory signals, these 
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monoclonal antibodies expose cancer cells as being “non-self” thus prompting the 
immune system to attack. Now, studies are focusing on combination therapies, which 
combine chemotherapeutics or other monoclonal antibodies with PD-1 and CTLA-4 
inhibitors to enhance the effectiveness of the drug. However, drawbacks and side effects 
to the therapy range from fatigue and nausea to development of autoimmune diseases. It 
brings forward that future studies will need a panel of predictive biomarkers to identify 
the best candidates for the immunotherapy. While there are many obstacles, such as a 
lower than expected efficacy of the immunotherapy, the progress made has important 
implications in the development of personalized medicine.  
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INTRODUCTION 
 
According to the American Cancer Society, cancer is the uncontrolled proliferation 
and spread of abnormal cells. It is also the second most common cause of death behind 
heart disease in the United States of America. It is expected that in 2017, approximately 
1.7 million new cases of cancer will be diagnosed and that half a million people will die 
from this disease (“Cancer Statistics,” n.d.). These numbers continue to rise, even though 
earlier diagnoses are possible and more precise treatments are available.   
The current treatments for cancer include: surgery, radiation therapy, chemotherapy, 
targeted therapy, stem cell transplant, precision medicine, and immunotherapy. While 
surgery, radiation therapy, and chemotherapy are the most common treatments, new 
research in the field of cancer treatment indicates the possibilities of designing treatments 
that are personalized and effective. Immunotherapy falls under this category in that it 
harnesses and stimulates a patient’s own immune system to attack and eliminate the 
cancer. There are various types of immunotherapies, all boosting different parts of the 
patient’s immune system (Abbas, Abul K., Lichtman, Andrew H., & Pillai, Shiv, n.d.). 
  
Adaptive Immunity: Using the Immune System 
 
Immunotherapy, which is defined as the “treatment of disease by inducing, 
enhancing, or suppressing an immune response,” is a novel approach that researchers 
have recently begun exploring and harnessing to fight cancer (“Immunotherapy,” 2016). 
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In regards to cancer, activation immunotherapies, or therapeutics that are designed to 
amplify an immune response, are used to activate the adaptive immune response against 
abnormal or cancerous cells. These cell-mediated immunotherapies disrupt the self-
tolerance mechanisms that are co-opted by cancer cells to protect themselves from T 
lymphocytes.  
Two inhibitory mechanisms that normal cells use to prevent apoptosis by cytotoxic T 
lymphocytes (CTL) are engagement of cytotoxic T lymphocyte antigen 4 (CTLA-4) 
receptors and programmed death 1 receptor and its ligand (PD-1, PD-L1). Previous 
treatments use antibodies against these two mechanisms to direct the patient’s own 
immune system to attack tumor-associated antigens (TAA) found on the surface of 
various cancer cells. Tumor-associated antigens are biomarkers that are found on the 
surface of cancer cells and that are recognized by the patient’s immune system. Once the 
antibody binds to the TAA, they can induce cell-mediated cytotoxicity by recruiting 
CTLs to the site of the cancer.  
Immunotherapy uses well known mechanisms of adaptive immunity. As seen in the 
Figure 1, T lymphocytes recognize CTLA-4 and PD-1 on cancer cells, which allows the 
cancer cells to evade subversion by the immune system. However, if there are antibodies 
against CTLA-4 and PD-1 and PD-L1 (on the T lymphocytes) then a T lymphocyte can 
be primed against the cancer cell and effectively destroy it.  
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Figure 1: The blockade of PD-1 and CTLA-4 signaling in tumor immunotherapy 
(Domagala-Kulawik, 2015).  
 
 
T cells recognize antigens presented by the major histocompatibility complex (MHC) on 
the surface of cancer cells through their T-cell receptor complexes (TCR). This first 
signal is not enough to turn on a T lymphocyte response, but a second signal delivered by 
a B7 costimulatory molecule, B7-H1 or B7-H2, is what facilitates the interaction between 
a T lymphocyte and cancer cell. CTLA-4 is upregulated shortly after T cell activation and 
initiates the negative signaling required to protect the cancer cell. The PD-1 receptor on 
the T lymphocyte also interacts with the PD-L1 ligand on the tumor cell. This 
receptor/ligand combination is upregulated on inflamed tissues and in the tumor 
microenvironment. This interaction leads to negative regulation and protection of the 
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cancer. Antibodies to this receptor and ligand prevent negative regulation and results in 
the preferential activation of T lymphocytes with a specificity for the tumor cells (Ribas, 
2012). The diagram below depicts the various areas that immunotherapy can target in 
fighting cancers.  
 
Figure 2: Multimodality in immunotherapy (Terando, Faries, & Morton, 2007). 
 
 
This thesis focuses on how current immunotherapies help the patient’s own 
adaptive immune system identify, target, and destroy existing tumor cells. Tumors exploit 
mechanisms that prevent autoimmunity in normal human cells to protect themselves from 
being discovered as abnormal cells. 
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PD-1/PD-L1 
 
As stated above, the tumor is able to overcome the cytotoxic effect of T lymphocytes 
by interacting with immune checkpoints, CTLA-4 and PD-L1, and creating inhibitory 
signals and causing negative regulation of the T lymphocytes. This thesis focuses more 
on the PD-1/PD-L1 interaction and the efficacy of “releasing the brakes” on the patient’s 
own adaptive immune system (Ribas, 2015). 
In order to keep healthy tissue unharmed and prevent autoimmunity, the immune 
system has a set of immune checkpoints to prevent over activation. The PD-1/PD-L1 
pathway is one such checkpoint. It works as an inhibitory T cell receptor that when 
engaged with its ligand, PD-L1, serves to protect the cell expressing the ligand, and 
causes apoptosis in the CTL that is attacking it. Tumor cells have managed to hijack this 
mechanism for their own protection (Ribas, 2012). One of the current experimental 
treatments are monoclonal antibodies against PD-1. Blocking the receptor on T 
lymphocytes prevents the interaction with the PD-L1 on tumor cells. Without this 
inhibitory signal, the CTLs are free to target and kill the existing tumor cells.  
Current research has shown how transgenic expression of PD-L1 on tumor cells has 
made them less susceptible to tumor-specific T lymphocytes and enhanced their 
tumorigenesis and invasiveness in mouse models. However, it has also been shown that 
with an anti-PD-1 monoclonal antibody (mAb), the effects were reversed. Injection with 
the mAb brought about significant suppression of growth in the tumor cell line as well as 
delayed expansion as compared to the control group (Iwai et al., 2002). 
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Figure 3: DBA/2 mice (10 mice per group) were inoculated s.c. with 3*10^6 
P815/PD-L1 cells and normal rat IgG (circles), or anti-PD-L1 mAb (squares) and 
were injected on days 1, 3, 5, and 7 at 0.1mg per mouse each time (Iwai et al., 2002).  
 
These findings are promising in that they may help target refractory tumors that are 
resistant to chemotherapy and inaccessible to surgery and radiation. Tumors that have 
developed resistance mechanisms such as local immune suppression have been shown to 
regress when treated with anti-PD-1 mAb. Figure 4 below shows the progression of a 
tumor when treated with a PD-1 antibody (Topalian, Hodi, et al., 2012). 
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Figure 4: Panel D shows a partial response in a patient with metastatic non-small 
cell lung carcinoma (NSCLC) of the non-squamous histologic type, who received 
anti-PD-1 antibody at a dose of 10mg per kilogram body weight. The arrowheads 
show initial progression in pulmonary lesions, followed by regression (an immune 
related pattern of response) (Topalian, Hodi, et al., 2012). 
 
 
The PD-1 receptor is especially abundant on the surface of non-small cell lung 
carcinomas, skin cancers, ovarian cancers, bladder cancers, and colorectal cancers. What 
has also been seen with the PD-1 receptor is the costimulatory B7-H1 molecules, which 
helps deliver a negative signal to the CTL, causing its apoptosis. Most notably is that B7-
H1 does not exist on normal, healthy tissues, making it a prime target for therapy. 
Immunohistochemical analysis shows that 20 out of 21 lung carcinomas, 22 out of 22 
melanomas, 20 out of 23 ovarian cancers, and 10 out of 19 colorectal cancers are positive 
for this B7-H1 costimulatory molecule (Dong et al., 2002). B7-H1 is also expressed on 
66% of the squamous cell carcinomas found on the head and neck (Strome et al., 2003). 
It seems that B7-H1 is upregulated on various tumors due to the effects of interferon 
gamma (IFNγ) in the tumor microenvironment (Topalian, Drake, & Pardoll, 2012). 
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Table 1: PD-1 and B7-H1/PD-L1 blocking agents currently in clinical testing 
(Robert et al., 2015) (www.clinicaltrials.gov). 
 
 
The tumor microenvironment also supports the production of T regulatory cells 
(Treg) in that Foxp3 is markedly increased on tumor cells and tumor infiltrating 
lymphocytes (TIL). As the population of Tregs is augmented, the tumor 
microenvironment moves towards creating M2 macrophages –macrophages involved in 
anti-inflammatory processes that also promote tissue growth- and production of IL-10 
and TGFβ cytokines that prevent inflammation and allow for tumors to escape detection 
by CTLs (Domagala-Kulawik, 2015). For this reason, immunotherapy that targets not 
only activation of T cells but also targeting and removal of an immunosuppressive 
environment, is most appealing for treating cancer.  
However, as with any type of therapy, there are side effects. Notable side effects 
of this therapy include fatigue, nausea, decreased appetite, vomiting, headaches, and 
dyspnea. More importantly, the following research also shows that the efficacy of 
immunotherapy is still lower than expected, hovering around 40% positive responses 
overall, but better prognosis in PD-1 positive tumors. It brings forward the question of 
having a panel of predictive biomarkers that can be used to identify the best candidates 
for the immunotherapy.  
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Drug Delivery  
 
As stated above, PD-1 and CTLA-4 are considered to be the main checkpoint 
molecules for effective immunotherapy in solid tumors. Recent research has shown that 
in terms of efficacy, PD-1 antibodies: nivolumab (OPDIVO), lambrolizumab 
(KEYTRUDA), and pidilizumab, have had moderate success in Phase I and II clinical 
trials (Ascierto, Simeone, Sznol, Fu, & Melero, 2010). Ipilimumab (YERVOY), the anti-
CTLA-4 IgG1 humanized antibody, binds to CTLA-4 and prevents the inhibition of 
CD28/B7 signaling. This leads to T cell activation and depletion of T regulatory cells, 
which in normal cancer related scenarios, help maintain the tumor microenvironment 
positively for the cancer. Similar to anti-PD-1 agents, the anti-CTLA-4 antibody has 
shown some benefits, particularly in combination with chemotherapy and other hormone 
therapy.  
Current therapeutics that exist in clinical phases include inhibitors to both PD-L1 
and PD-1. While the mechanism for these drugs vary slightly, the effect is the same: 
activation of the patient’s own anti-tumorigenic immune response (Robert et al., 2015). 
One of the goals of this thesis is to present these drugs and evaluate their efficacy.  
 
Specific Aims  
 
Immunotherapy is quickly making its way from bench to bedside. The goal is to 
use the patient’s own immune system to attack abnormal cancer cells. This thesis 
discusses the importance of immunotherapy in cancer treatment and compare current 
 10 
cancer therapeutics to immunotherapy. It also reviews clinical trials that have been 
conducted and their efficacy in various cancers, such as ovarian cancer, colon cancer, 
non-small cell lung carcinoma, and melanoma. Finally, the thesis evaluates the risks and 
roadblocks of immunotherapy and discuss the future direction of this type of therapy.  
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PUBLISHED STUDIES  
 
Current research shows that there are various Food and Drug Administration 
(FDA) approved monoclonal antibodies against CTLA-4 and PD-1/PD-L1. Antibodies 
against PD-1 have also been shown to have some efficacy in non-small cell lung 
carcinoma (NSCLC), renal cell carcinoma (RCC), ovarian cancers, bladder cancer, 
Hodgkin’s lymphoma, and melanomas (Voena & Chiarle, 2016). Both PD-1/PD-L1 and 
CTLA-4 utilize CD8+ T lymphocytes to mediate the anti-tumor effects. CD8+ T 
lymphocytes, also known as cytotoxic T lymphocytes (CTL), recognize and destroy 
tumor cells through interaction of major histocompatibility complex (MHC) I complexes 
and T cell receptor (TCR) complexes. The MHC I complexes present tumor-associated 
antigens (TAA) to the CTLs, activating them to become tumor reactive. However, cancer 
cells utilize the cell’s protection mechanisms against autoimmunity by engaging the 
CTLA-4 and PD-1/PD-L1 protective mechanisms. For this reason, mAb against PD-1 
and PD-L1 in combination with polyinosinic-polycytidylic acid (poly-IC), a known 
immunostimulant that is expressed in the membrane of B cells, macrophages, and 
dendritic cells, have been shown to be highly effective against established tumors 
(Nagato & Celis, 2014). 
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Figure 5: Co-administration of poly-IC and blocking antibodies of the PD-1/PD-L1 
pathways may enhance anticancer CTL responses. (A) Poly-IC stimulates dendritic 
cells (DC) to increase expression of peptide/MHC complexes and secrete cytokines 
such as IFNγ to enhance activation, proliferation, and maturation of CTLs. 
Blockade of PD-1/PD-L1 with mAb helps CTLs expand and become more potent 
effector cells. (B) Poly-IC activates DCs at tumor site and enhances tumor antigen 
cross-presentation, leading to the generation of new CTL responses. The blockade of 
PD-1/PD-L1 pathway enhances the effector phase of CTL responses (Nagato & 
Celis, 2014). 
 
Dendritic cells are attractive vectors for tumor immunotherapy, due to their 
unique potential to induce primary immune responses by directly priming naïve CD4+ 
and CD8+ T lymphocytes. Their ability to efficiently uptake, process, and present 
antigens on MHC class I and II with costimulatory molecules to naïve T lymphocytes has 
made them targets for inducing antitumor T cells (Cioca, Deak, Cioca, & Paunescu, 
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2006). Tumors have the ability to develop multiple resistance mechanisms such as 
suppressing the local immune system, inducing tolerance, and causing systemic 
dysfunction in T cell signaling.  
Novel PD-1/PD-L1 clinical trials have shown that 20-25% of patients with 
melanoma, NSCLC, RCC, prostate cancer, and colorectal cancer showed objective 
responses to the treatment. As seen in Table 2, the blockade of PD-L1 produced both 
durable tumor regression (6-17%) and prolonged (greater than 24 weeks) disease 
stabilization in patients with metastatic NSCLC, melanoma, RCC, and ovarian cancer 
(Brahmer et al., 2012). 
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Table 2: Clinical activity of anti-PD-L1 antibody in the efficacy population. The 
efficacy population included 160 patients in whom a response could be evaluated. 
These patients had measurable disease at baseline tumor assessment and at least one 
of the following- an assessment of tumor burden during the study, clinical 
progression, or death (Brahmer et al., 2012). 
 
However, as shown in Table 3, trials have also shown that 5% of participants 
discontinued PD-1/PD-L1 mAb due to adverse events (AE) such as fatigue, decreased 
appetite, diarrhea, nausea, cough, dyspnea, constipation, vomiting, rash, pyrexia, 
headache, and autoimmunity (Topalian, Hodi, et al., 2012). 
 
Table 3: Treatment related adverse events of special interest that occurred in at least 
1% of all treated patients. Patients were given a dose of PD-1 mAb at 0.1-10mg/kg 
of body weight every two weeks (one cycle) for up to 12 cycles (Topalian, Hodi, et 
al., 2012). 
 
 
Other studies have also shown the involvement of B7-H1, a costimulatory 
molecule that is a member of the B7 family. It is involved in regulation of cellular and 
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humoral responses through PD-1 receptors on activated T and B lymphocytes. What is 
key about this discovery, is that normal human tissues do not express B7-H1, they are 
only found on macrophages. However, B7-H1 is upregulated by IFNγ on the surface of 
tumor cells, especially in lung carcinomas, ovarian cancers, colon cancers, and 
melanomas. In vitro, the interaction between B7-H1 and CD28 causes T cell apoptosis. 
Immunohistochemical analysis has shown B7-H1 immunoreactivity on 20/21 lung 
carcinoma patients, 20/23 ovarian cancer patients, 10/19 colon cancer patients, and 22/22 
melanoma patients. It was also found that while B7-H1 was overexpressed on these 
cancers, it was not on the surrounding normal cells, making it a target for immunotherapy 
(Dong et al., 2002). Perhaps, co-targeting of PD-1/PD-L1 and B7-H1 with monoclonal 
antibodies will activate CTLs to become more specific towards the tumor cells they need 
to destroy. 
 
Figure 6: B7-H1 expression in normal and cancer tissues. Snap frozen specimens of 
human tissues, normal or from lung or ovary carcinomas and melanomas, were 
examined immunohistochemically using monoclonal antibody (5H1) against B7-H1 
or control mouse IgG1 (mIgG1). Adjacent sections were also stained with 
hematoxylin and eosin (H & E) for comparison. (A) B7-H1 immunoreactivity was 
not found in liver parenchyma, the lung or tonsil lymphocytes. B7-H1 expression 
was limited to macrophage-like cells (arrows) in the Kupffer cells of the liver, in the 
lung, and in paracortical macrophages near a germinal center (GC) in the tonsil. No 
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B7-H1 expression is found in normal breast, colon, kidney, uterus, and muscle or 
pancreas tissue. Frozen sections of B7-H1/624mel cell pellets were used as positive 
controls. (B) In a lung cancer sample (top), B7- H1 immunoreactivity was limited to 
the tumor plasma membrane or cytoplasm and was not seen in normal alveolar 
cells. A few B7-H1-positive pulmonary macrophages are indicated (arrows). In 
ovarian adenocarcinoma cells (middle), B7-H1 immunoreactivity is in the plasma 
membrane. In lymph nodes containing metastatic melanoma cells (bottom), B7-H1-
positive tumor cells formed a boundary at the interface with B7-H1 negative 
lymphocytes (Dong et al., 2002). 
 
 
Colon Cancer 
One of the cancers that has been shown to have some success with 
immunotherapy is colon cancer. A cancer with complex genetic alterations, starting with 
a mutation in the adenomatous polyposis gene (APC) which then leads to mutations in 
oncogenes such as c-myc and cyclin D1, is the third most common cancer in the United 
States and the second most common mortality due to cancer in men. Currently, colon 
cancer has a five year survivability rate at 65%, but this directly relates to the stage of 
cancer. For people who are discovered and begin treatment at Stage I, their survivability 
is 95%, while people who are discovered at Stage IV have a 5 year survivability at 10%. 
Predictors for the worst outcomes in colon cancer include: a tumor size greater than 5cm, 
a disease free interval of less than 1 year, more than one tumor, primary lymph node 
positivity, and a carcinoembryonic antigen (CEA) level of greater than 200ng/mL. Colon 
cancer develops through genetic factors (mutations in oncogenes, DNA mismatch, 
abnormal methylation of tumor suppressor genes), environmental exposures (diet high in 
red meat and fat, low fiber, low intake of fruits), and other inflammatory conditions of the 
gastrointestinal system (“Colon Cancer,” 2017). The most common genetic mutations 
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that mark colon cancer include, APC, KRAS, P5, and mismatch repair genes (MMR). 
Many of these tumors, while having different genetic alterations, different host 
backgrounds, and different evolutions, show the same clinical presentation (Bertucci et 
al., 2004). 
While previous studies in immunotherapeutics have shown anti-CTLA-4 and anti-
PD-1/PD-L1 as being somewhat effective in the treatment of colon cancer, other studies 
have shown that combination therapies with other mAb or chemotherapy have a much 
higher efficacy in targeting and removing the tumor. This is due to the fact that the tumor, 
by co-opting mechanisms that prevent autoimmunity, creates a microenvironment that 
produces cytokines that are vital to the development of T regulatory cells (Tregs), which 
play a vital role in maintaining peripheral self-tolerance. Zhou et.al, showed how a drug 
that blocks B7-H1/H2 along with an anti-PD-1/PD-L1 mAb can alter the balance between 
Treg cells and CTLs in the tumor microenvironment that facilitates destruction of the 
cancer. In this study, anti-B7-H1/H2 mAb were administered to mice with either prostate 
cancer or MC38 colon cancer. What they found was that short term administration of this 
mAb leads to significant inhibition of primary tumor growth and reduction in size of 
metastatic lesions. The antibody also leads to transient reduction of Treg cells in the 
thymus and periphery and production of TAA specific CTL effectors against the tumor 
cells (Zhou, Zheng, Zhang, Liu, & Zheng, 2009). 
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Figure 7: Anti-B7-H1/H2 antibody treatment reduced Treg cells in both the thymus 
and periphery of normal mice and delayed the development of palpable tumors in 
the mice. C57BL/6 mice were injected intraperitoneally with either B7-H1/H2 mAbs 
or control IgG at 6 weeks old, 5 times a day, and every other day. The mice were 
sacrificed 8 days after the last injection. Thymocytes and splenocytes were harvested 
and analyzed by flow cytometry. (A) anti-B7-H1/H2 antibody treatment did not 
alter the number of thymocytes, spleen cells, and CD4+/CD8+ subsets. (B) anti-B7-
H1/H2 antibody treatment reduced CD25+Foxp3+ cells (Treg) in both thymus and 
spleen (Zhou et al., 2009). 
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From Figure 7, treatment with mAb against B7-H1/H2 lead to a transient 
reduction of Treg cells, which allows for enhanced tumor specific cytotoxicity through 
the activation of CTLs. As seen below in Figure 8, the treatment with this antibody also 
delayed the growth of the cancer without autoimmune effects. 
 
Figure 8: Anti-B7-H1/H2 antibody treatments of mice with established prostate 
cancer inhibited cancer progression. (C) anti-B7 treatment initiated at 25 week old 
TRAMP mice transiently depleted Treg. MRI image of mice at 25 and 33 weeks (8 
weeks after starting treatment with either control or mAb). (D) Kaplan-Meier 
analysis for incidence of palpable tumors treated with either control 
immunoglobulin or anti-B7 antibodies at age 25 weeks (Zhou et al., 2009). 
 
Anti-B7 antibodies have also been effective in treating MC38 colon cancer. 
Figure 9 below shows 8 week old male C57BL/6 mice being injected subcutaneously 
with MC38 cells and then being divided by resulting tumor size. The groups were then 
injected with either anti-B7-H1/H2 antibodies or the control IgG. After the first week of 
treatment, CD4+FoxP3+CD25+ Treg cells began to decrease. The antibody treatment 
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also slowed down the growth of the MC38 tumor. Overall, Zhou et al, showed how the 
use of antibodies against costimulatory molecules such as B7-H1 and B7-H1 improves 
the efficacy and specificity of cytotoxic lymphocytes against prostate and colon cancers. 
 
Figure 9: Anti-B7-H1/H2 mAb treatments of mice bearing MC28 colon carcinoma 
(Zhou et al., 2009). 
 
Another recent study of immunotherapy in colon carcinomas discusses how colon 
cancer cells deregulate the Fas signaling pathway. Fas is a trimeric membrane-bound 
protein that is a member of the tumor necrosis factor family. It is highly expressed on 
colon cells and interaction with its ligand, FasL, directs CTL cytotoxicity towards tumor 
cells. In this study, novel ceramide analogs were used to modulate Fas function such that 
colon carcinoma cells could be sensitized to FasL mediated apoptosis. As a central 
metabolite of sphingolipid metabolism, Fas plays a role in mediating multiple cellular 
functions such as cell proliferation, apoptosis, motility, stress responses, and immunity. A 
functional deficiency of Fas limits FasL and ceramide analogs in inducing apoptosis. As 
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shown in Figure 10 below, Fas protein level is downregulated in human colon 
carcinomas, and there is a complete loss in expression metastatic disease. 
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Figure 10: Human colon carcinomas were stained with anti-Fas mAb. The brown 
color indicates Fas protein level, with counterstaining in hematoxylin blue. A1-A4 
are normal tissues from four patients, B1-B4 are adenomas, C1-C4 are primary 
invasive adenocarcinoma, D1-D4 are colorectal adenocarcinoma metastatic to 
lymph nodes, E1-E4 are colorectal adenocarcinoma metastatic to liver (Coe et al., 
2016). 
 
As FasL on CTLs plays a main role in tumor suppression, it is thought that colon 
carcinomas use the down regulation of Fas protein as a mechanism to escape destruction 
by the immune system. However, it was found that ceramide analogs sensitize colon 
carcinomas to FasL mediated apoptosis. Of the various analogs that were tested, the 
following: IG4, IG7, IG8, IG14, IG17, and IG19, were found to effectively increase the 
sensitivity of colon cancer lines to apoptosis.  
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Figure 11: Identification of novel ceramide analogs that sensitize human colon 
carcinoma cells to FasL-induced apoptosis. (A)Colon carcinoma lines SW480, RKO, 
and HCT116 were cultured with ceramide analogs, with or without MegaFasL for 
24 hours. Shown flow cytometry plots are representative of apoptosis. (B) 
Quantification of apoptotic cell death (Coe et al., 2016). 
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These ceramide analogs have also been found to increase FasL induced NF-kB 
activation. This allow creation of a microenvironment that is detrimental to the tumor 
cells, but beneficial to FasL induced, CTL mediated apoptosis. As seen in the figure 
below, these analogs are capable of increasing tumor lysis. 
 
Figure 12: Identification of novel ceramide analogs that increase efficacy of tumor-
specific CTL-mediated tumor lysis. (A) Mouse colon cancer cells were labeled with 
CFSE and seeded. Tumor specific perforing deficient pfpCTLs were added to tumor 
culture and cultured for 24 hours. (B) Quantification of CTL-induced tumor cell 
death kinetics. (C) CT26 cells were labeled with CFSE and cultured in the presence 
of ceramide analogs with or without pfpCTLs for 24 hours. (D) Quantification of 
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CTL induced tumor cell death in the absence or presence of ceramide analogs (Coe 
et al., 2016). 
 
As Fas expression decreases in colon cancer cells as the cancer progresses, one 
potential therapeutic would be to restore Fas expression to prevent cancer progression. 
However, as seen above in Figure 12, most cancer cells still express enough functional 
Fas and the level of Fas expression does not directly correlate to the tumor cells 
sensitivity to FasL induced apoptosis. Coe et al., has shown how five novel ceramide 
analogs increased FasL induced apoptosis in human colon carcinoma by sensitizing the 
cells. The study showed that there is no apparent toxicity in applying these analogs, even 
at a dose as high as 100mg/kg body weight. As the current patient objective response for 
PD-1 mAb is 6-17% in colorectal cancers, perhaps in the future, a combinatorial therapy 
with PD-1 mAb or CTLA-4 mAb and ceramide analogs will effectively target and 
sensitize human colon carcinoma cells to CTL mediated apoptosis (Coe et al., 2016). 
Other studies have researched the effect of administering CTLA-4 mAb along 
with depletion of Treg cells as a new strategy for cancer immunotherapy. It was 
hypothesized that combination therapy of a CTLA-4 blocker and depletion of 
CD4+CD25+ Treg cells would improve the efficacy of a DC-based vaccine in the 
treatment of colon carcinoma. It was found that a systematic application of an anti-CD25 
antibody prior to a vaccination with a CTLA-4 antibody leads to improved tumor free 
survival as compared to application of a CTLA-4 mAb alone. 
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Figure 13: Prior depletion of CD25+ T cells or systemic administration of anti-
CTLA-4 antibody improves the therapeutic potential of DC-based vaccine. Mice 
were transplanted with 5*10^5 non-transfected parental MC38 tumor cells(A) and 
mice bearing 7 day established tumors were divided into several treatment groups 
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and immunized as described. (B) *P<0.04, (C) established tumors were divided into 
several treatment groups and immunized. Mice were sacrificed when tumors 
became ulcerated or reached a diameter >20mm and survival was recorded (Saha & 
Chatterjee, 2010). 
 
 
The use of combination therapy consisting of DC based vaccine and blockage of immune 
regulatory pathways resulted in enhanced induction of peptide specific and CEA specific 
Th1 response that correlated with improved survival.  
 
Figure 14: The use of combination therapy consisting of DC based vaccine and 
blockade of immune regulatory pathways resulted in enhanced induction of peptide-
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specific and CEA-specific Th1 response that correlated with improved survival. (A) 
CAP1-6D peptide-pulsed or un-pulsed T2 cells, (B) DCs pulsed with 3H1, CEA, 
CAP1-6D, (C) splenocytes were isolated from different groups of immunized mice 5 
days after the final immunization and were stimulated in vitro in the presence of 
DCs pulsed with 3H1, CEA, CAP1-6D peptides (Saha & Chatterjee, 2010). 
 
Results from this study suggested that combination therapy strongly enhanced tumor 
specific immune responses of DC-based therapy. However, a vital part of immune 
therapy is the development of antigen-specific memory after administration of a vaccine. 
Figure 15 shows how the depletion of CD25+ cells led to an increased expression of 
CD8+ cells as well as increased expression of CD44 on cells. These results suggest that 
in this murine model, there was development of antigen-specific memory T cells. 
 
Figure 15: Up-regulated surface expression of memory phenotype Ly-6C and CD4 
in mice that have been cured of MC38 CEA-A2Kb tumors (Saha & Chatterjee, 
2010). 
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Saha and Chatterjee, et al. have shown that the addition of therapeutics that interfere with 
the mechanisms that normally keep the immune system in check (such as Treg cells), 
improves the efficacy of monoclonal antibodies such as anti-CTLA-4 against colon 
carcinomas. While the vaccines require further optimization and refinement, studies have 
shown that if the host tolerance to the tumor can be broken first by dysregulating the 
mechanisms in place, antibodies that stimulate cytotoxic effects of T cells can be more 
effective in targeting and removing tumor cells (Saha & Chatterjee, 2010). 
 
Ovarian Cancer 
 
Ovarian cancer is the most common cause of cancer death from a gynecologic tumor. 
Every year, 100,000 women lose their battle against ovarian cancer, and 200,000 women 
just begin to fight it. While 70% of ovarian cancers develop from the serous cells in the 
fallopian tubes, tumors can also develop from the endometrial cells, mucinous cells of the 
cervix, and clear cells of the mesonephros (“Cancer Statistics,” n.d.). Due to the location 
of this cancer, metastases are common and are usually found on the surface of the liver, 
mesentery and serosa of the bowels, pelvic lymph nodes, and lungs. Unfortunately, 
ovarian cancer is often discovered in its late stages because of the tumors ability to hide 
its size in the peritoneal cavity and the fact that ovarian cancer has minimal symptoms. 
These symptoms, which include bloating, pressure on the bladder, constipation, acid 
reflux, weight loss, and tiredness, are often misdiagnosed as other problems. The current 
treatments for ovarian cancer include aggressive debulking surgery followed by 
chemotherapy. If the lesion is less than 2cm and has no metastases, the patient has a 
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better prognosis. Chemotherapy, which is used for all stages of ovarian cancer except 
Stage I, is usually a combination of a platinum compound and taxane. Although this is 
effective in 80% of patients, 60% of patients tend to relapse and of those, less than 40% 
will survive beyond 5 years (Wei, Zhao, Hellstrom, Hellstrom, & Guo, 2014). Overall, 
patients who suffer from ovarian cancer have a 46% 5 year survival rate (“Ovarian 
Cancer,” 2016). 
Markers of ovarian cancer include mutations in the BRCA1/BRCA2, found in 10% of 
fallopian tube cancers, NF1, RB1, and CDK12. Almost all tumors have mutations in the 
P53 gene, a common tumor suppressor gene. There is also a small 4-5% increase in risk 
in developing ovarian cancer if a family member also had it. Overall, about half of 
ovarian cancers tend to develop because of defective homologous recombination 
(Zakharia, Rahma, & Khleif, 2014). Studies and clinical trials in immunotherapeutics for 
ovarian cancer have only shown a modest benefit when used as a monotherapy, but when 
used in combination with checkpoint inhibitors, chemotherapy, and other inhibitors of 
costimulatory molecules, the antitumor efficacy is greatly enhanced (Hardwick, Frankel, 
& Cristea, 2016).   
Recent studies have shown that in addition to using anti-PD-1/PD-L1 mAb, 
simultaneous targeting of CD137, a costimulatory molecule, and treatment with cisplatin 
enhanced the antitumor response in a mouse ovarian carcinoma. In order to develop an 
effective anticancer response, APCs must be able to access and present the TAAs to 
CTLs in order to activate them. However, tumors develop blocking mechanisms for 
nearly all the steps of the cycle. To overcome this problem, removal of the 
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immunosuppressive environment must coincide with the antitumor response. In this 
study, CD137 was simultaneously targeted alongside application of an anti-PD-1 mAb 
and then the mice were treated with cisplatin to further enhance the effect. 
 
Figure 16: Induction of an anticancer immune response by dual targeting of CD137 
costimulatory and PD-1 co-inhibitory molecules in combination with conventional 
cancer therapy (Wei et al., 2014). 
 
Dual targeting of CD137/PD-1 abolishes the local suppression and leads to functional 
rescue and expansion of effector T cells that subsequently kill the cancer cells. This 
synergistic effect further improves after treatment with cisplatin or other therapies, such 
as tumor vaccines and radiation (Wei et al., 2014). Some current ovarian cancer vaccines 
are shown in Table 4. 
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Table 4: Completed clinical trials in ovarian cancer (Zakharia et al., 2014). 
 
 
Ovarian cancer also has become an appealing target for immunotherapeutics 
because of its tumor associated antigens (TAA) that are recognized by T cells. There 
have been four main motifs of the TAAs associated with ovarian cancer: antigen protein 
with a point mutation, such as p53, germ cell antigens that are expressed on normal 
testicular cells, overexpressed proteins such as Her2/neu, and antigens with abnormal 
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posttranslational modifications such as under glycosylated mucin. Targeting these 
specific antigens along with targeting of PD-1/PD-L1 may lead to a synergistic effect in 
antitumor activity. Table 5 below shows some of the results of clinical trials involving 
PD-1/PD-L1 and CTLA-4 antibodies (Zakharia et al., 2014). 
 
 
Table 5: Completed trials using immune modulators in ovarian cancer (Zakharia et 
al., 2014). 
 
Another recent study shows how combination therapy of a monoclonal antibody 
against PD-1 with an anticancer agent, Trabectedin (ET-743) increases anti-tumor 
activity in murine ovarian cancer. Trabectedin is a synthetic, marine-derived anti-cancer 
agent that binds the minor groove of DNA and disrupts the cell cycle. It is also able to 
modulate the tumor microenvironment by depleting pro-tumor monocytes (TAM) and 
myeloid derived suppressor cells (MDSC). As discussed before, while a platinum-taxane 
chemotherapy is effective for 80% of the population, more than 60% of these patients 
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relapse and 5-year mortality remains below 50%. As with other cancers, anti-PD-1 
treatment has modest results in ovarian cancer, but when combined with checkpoint 
inhibitors and other anticancer agents, its effect can be enhanced (Guo, Wang, Meng, Li, 
& Zhang, 2015). In this study, Trabectedin was injected at 200ug/kg body weight, once a 
week, for three weeks followed by α-PD-1 mAb twice per week, for two weeks. All of 
this was started 10 days after tumor injection. The mice were regularly weighed for tumor 
growth and once the tumor reached a weight greater than 30% of the mouse, it was 
removed and analyzed. The results are seen in Figure 17 below (Guo et al., 2015). 
 
Figure 17: Combined treatment with Trabectedin and a-PD-1 mAb mounted a 
durable tumor specific immunity. (A) Schematic regimen for combination treatment 
in ID8 tumor model (B) treated mice (C) overall survival of mice (D) long term 
surviving mice from combination group (E) naïve mice challenged with ID8 or TC1 
tumor cells (F) independent experiment supporting data (Guo et al., 2015). 
 
 
Results showed that a combined treatment of ET-743 and PD-1 mAb synergistically 
induced a durable antitumor effect. While ET-743 only inhibited tumor growth alone, and 
PD-1 had an insignificant effect of tumor cell depletion, together, the two treatments 
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increased survivability by 50% and they increased the ratios of effector T cells to 
immunosuppressive cells, such as TAM, MSDC, and Treg cells, in the tumor 
microenvironment. In vivo treatment of Trabectedin also increased PD-1 expression on 
tumor cells, making them more susceptible to the PD-1 mAb (Guo et al., 2015). This 
study shows that while antibodies to PD-1/PD-L1 are novel therapeutics, they work much 
better as a cancer treatment when combined with molecules that remove host 
immunosuppression and deregulate the tumor microenvironment. 
 
Figure 18: Mice treated with combined Trabectedin and a-PD-1 mAb developed a 
tumor antigen specific CTL response. (A) Splenocytes assessed after tumor 
challenge (B) splenocytes irradiated and pulsed with mesothelin peptide (C) target 
cells (D) the killing activity of re-stimulated splenocytes from combination treated 
mice (Guo et al., 2015). 
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Another costimulatory molecule used with PD-1/PD-L1 mAb is OX40. OX40 is 
upregulated on activated T cells, and has the ability to increase clonal expansion, 
survival, and cytokine production of CTLs. What’s interesting in this study is that alone, 
PD-1 and OX40 alone were unable to produce an effective antitumor response, but 
together, they were able to inhibit tumor growth and also prevent growth in 60% of the 
mice for 90 days after inoculation. It was seen that the combined therapy increased CD4+ 
and CD8+ cells and reduced CD4+FoxP3+ Treg cells (Guo et al., 2014). 
 
Figure 19: Treatment of combined anti-PD-1/OX40 mAb induced tumor specific 
long-lasting immunity against ID8 ovaria cancer (Guo et al., 2014). 
 
Overall, mice treated with anti-PD-1/OX40 mAbs developed a tumor antigen specific 
CTL response. The increased antitumor efficacy was due to the removal of the brakes on 
effector T cells by blocking PD-1 on tumor cells and also because OX40 helped to 
promote an environment that helped proliferation, survival, and cytokine production on 
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the T cells. The next steps in this study would be to evaluate toxicity of both PD-1 mAb 
and OX40 mAb and fine tune the dosage to elicit the best response from ovarian cancer 
patients (Guo et al., 2014). 
Ovarian cancer is the leading cause of death in gynecologic cancers, and current 
treatments are aggressive surgery followed by a combination chemotherapy of platinum-
taxane. Unfortunately, many patients relapse and the 5-year mortality rate remains high. 
While immunotherapy is an appealing target, most cancers tend to be less immunogenic 
because of how they co-opt immunosuppressive and self-tolerance inducing mechanisms 
(Schwab, English, Roque, Pasternak, & Santin, 2014). Because of this, studies have 
shown that combination therapy with mAbs against PD-1 as well as against other 
molecules, such as OX40, B7, CD25, can help restore immunogenicity to tumors and 
alter their microenvironment. Thus, what was once an immunosuppressive area, can be 
more receptive towards CTLs and other activated T lymphocytes that aid in the 
destruction of the cancer. 
 
Non-Small Cell Lung Carcinoma 
 
As the second most common malignancy in the United States, lung carcinomas 
arise from peribronchial locations and infiltrate the bronchial submucosa. They fall into 
two categories, small cell lung carcinoma (SCLC) or non-small cell carcinoma (NSCLC). 
15% of all lung cancers are SCLC and 85% fall under NSCLC. Ninety-eight percent of 
all lung cancer patients have some smoking history, and unfortunately, lung cancer 
frequently metastasizes to areas that include the mediastinal lymph nodes, liver, bone, 
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and brain. At the time of presentation, 60-70% of patients have clinically disseminated 
disease or extensive disease. Those patients who have extensive disease, which is 
incurable, their survival is 20% at 7 months, and 2% at 5 years (“Small Cell Lung 
Cancer,” 2016). This thesis focuses on NSCLC, which includes squamous cell 
carcinoma, adenocarcinoma, and large-cell carcinoma. Figure 20 below details the 
progress from normal cells to cancer. 
 
Figure 20: Lung cancer pathophysiology (“Lung cancer | McMaster 
Pathophysiology Review,” n.d.). 
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Current treatments for NSCLC are surgery, radiation, and chemotherapy. Many 
patients have a poor prognosis because of relapse, greater than 10% body weight loss, 
and ionic imbalances (“Lung cancer | McMaster Pathophysiology Review,” n.d.). 
Immunotherapeutics have become an appealing goal for this kind of cancer because of its 
low survivability and dissemination.  
As stated earlier, PD-1 is an inhibitory pathway that is exploited by cancers to 
prevent recognition and removal by CTLs. One current immunotherapeutic that is 
currently FDA-approved is nivolumab (OPDIVO), an anti-PD-1 mAb that binds PD-1 
and disrupts interaction with PD-L1 and PD-L2. By doing this, it augments the antitumor 
response. A Phase II clinical trial assessed the efficacy of this treatment in NSCLC in 
patients that underwent multiple treatments with poor outcomes. Patients received 
nivolumab 3mg/kg body weight as an intravenous injection every two weeks (1 cycle) 
until disease progression or unacceptable toxic side effects. Of the 117 patients that were 
treated, 17 of them had an objective response to the antibody, 30 had stable disease, 51 
continued to have progressive disease, and 7 had an indeterminate response to the 
antibody. 
 40 
 
Figure 21: Kaplan-Meier analysis of progression-free survival and overall survival 
in the group (Rizvi et al., 2015). 
 
Adverse events noted throughout this trial included fatigue, decreased appetite, 
and nausea. Those patients with a Grade 3-4 disease presented with fatigue, pneumonitis, 
and diarrhea. Overall, the study showed that nivolumab monotherapy has clinical 
significance and an acceptable safety profile for patients with NSCLC. With no other 
treatments available for patients who have gone through chemotherapy more than twice, 
nivolumab is a step in the right direction for treatment of NSCLC. However, one of the 
points made by the study was that the tumor microenvironment was complicated and that 
perhaps dysregulation of its immunosuppressive nature would allow nivolumab to have 
better results (Rizvi et al., 2015). 
Efforts to improve the effectiveness of NSCLC treatment have also started to 
focus on TAAs, and how they play a role in improving targeting in immunotherapy. 
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Targeting highly expressed or overexpressed TAAs alongside the use of PD-1/PD-L1 or 
CTLA-4 mAbs could lead to a better prognosis in NSCLC (Karanikas et al., 2008). 
Costimulatory molecules are another target of immunotherapy to augment the effect of 
PD-1 mAbs. The B7 family is one of the prominent targets, with new members being 
discovered routinely. One such member is HHLA2, found on 62.8% on NSCLC. What is 
most important, is that HHLA2 was not found on normal lung tissue, such as type 1 and 2 
alveolar cells, endothelial cells, and smooth muscle cells, and only on tumor specimens. 
68.6% of adenocarcinomas, 35.45% on squamous cell carcinomas, 11.1% on large-cell 
carcinomas (Cheng et al., 2017). 
 
Table 6: Clinical characteristics of HHLA2 expression in patients with lung cancers 
from the discovery and validation cohorts (Cheng et al., 2017). 
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It was also seen that HHLA2 expression is associated with mutations in EGFR and 
KRAS, which are common mutations found in NSCLCs. HHLA2 was found to coincide 
with 25.6% of EGFR mutated and 62.9% KRAS mutated NSCLCs. 
 
Figure 22: HHLA2 positive cases and pairwise comparison with discovery cohort 
and validation cohort (Cheng et al., 2017). 
 
While HHLA2 is an appealing target because of its expression on tumor cells, there are 
limitations because it is unknown how environmental factors affect HHLA2 expression, 
as well as how HHLA2 interacts with other T cell subsets and costimulatory/coinhibitory 
molecules found in lung carcinomas (Cheng et al., 2017). B7-H1 is another potent 
immunoinhibitory molecule in the B7 family. Like HHLA2, it is a promising target for 
immunotherapies, as the interaction between B7-H1 and PD-1 maintains an 
immunosuppressive tumor environment. Like HHLA2, B7-H1 is also highly expressed 
on lung cancer cells, specifically adenocarcinomas. A study that investigated blocking 
B7-H1 with a monoclonal antibody showed how both tumor growth was inhibited, and 
also how T cell counts were increased in the tumor microenvironment. 
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Figure 23: Anti-B7-H1 antibody inhibition of tumor growth in vivo (Chen, Huang, 
Hang, Pan, & Ma, 2016). 
 
 
Figure 24: Representative flow graphs and results of quantitative analysis (Chen et 
al., 2016). 
 
The study provided novel evidence for co-inhibitory activity of B7-H1 in lung cancer. 
While tumor growth was modestly inhibited, this shows that perhaps combinatorial 
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therapy of anti-B7-H1 mAb with other immunostimulatory agents could enhance 
anticancer activity (Chen et al., 2016).  
Currently, some of the most successful immune checkpoint inhibitors are mAb 
that bind to either PD-1/PD-L1 or some other costimulatory molecule. Table 7 highlights 
some of the response rates to various PD-1 inhibitors as seen through clinical trials. 
 
Table 7: Response rates to anti-PD-1 and overall survival in NSCLC (Grigg & Rizvi, 
2016, p. 1). 
 
However, 11% of these patients had serious adverse events (SAE) such as development 
of autoimmune diseases or death, and upwards of 40% of patients showed common AEs 
such as fatigue, decreased appetite, and diarrhea. Finally, while PD-1 mAb alone shows 
modest efficacy, combined with radiation therapy and chemotherapy, it has shown 
increased antitumor activity (Grigg & Rizvi, 2016). 
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Melanoma 
 
The final cancer that this thesis examines in regards to immunotherapy, is 
melanoma. Melanoma is a malignant tumor of melanocytes, a pigment producing cell 
found in the deep layer of the epidermis. Dysregulation of melanocyte stem cells leads to 
rapid proliferation and growth. Seventy-five percent of melanomas have functional 
mutations in the RAS-RAF-MAPK pathways that lead to tumor production (Regad, 
2013). Risk factors for melanoma include: UV exposure, family history, fair skin, 
numerous nevi – birthmarks or moles, and immunosuppression due to organ transplant or 
AIDS. Globally, melanoma results in 55,000 deaths a year, making it the most dangerous 
type of skin cancer. Table 8 depicts the different kinds of melanoma and their 
morphology. 
 
Table 8: Location, morphology, and pathophysiology of melanoma subsets 
(“Melanoma | McMaster Pathophysiology Review,” n.d.). 
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Figure 25 below details the development of melanoma.  
 
Figure 25: Development of melanoma from benign nevus to metastatic disease 
(“Melanoma | McMaster Pathophysiology Review,” n.d.). 
 
Current treatments are surgical excision, regional lymph node removal, radiation 
therapy, chemotherapy, and most recently, immunotherapy (“Melanoma | McMaster 
Pathophysiology Review,” n.d.).  
Antagonistic antibodies to PD-1 and PD-L1 in melanoma have shown clinical 
benefits and tolerability. Some of the available therapies include nivolumab (OPDIVO), 
pembrolizumab (KEYTRUDA), and pidilizumab, which are anti-PD-1 antibodies that 
have been shown to be effective in melanoma as well as renal cell carcinoma, lymphoma, 
and NSCLC. 
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Table 9: Anti-PD-1 agents in clinical development (Homet Moreno, Parisi, Robert, 
& Ribas, 2015, p. -1). 
 
PD-1 has high selectivity for immune suppression, which means better specificity 
for the tumor as compared to CTLA-4. This also leads to fewer or milder adverse events. 
PD-1 also plays a role in preventing autoimmunity, which is seen by its ability to limit T 
cell activation, enhance Treg cell proliferation, and decrease the activity of natural killer 
(NK) cells. In patients with previously treated melanoma, the objective response to anti-
PD-1 mAbs ranged from 28%, at the lowest dosage of the drug, to 41%, at the highest 
dosage of the drug. As expected, there were some immune related AEs, most of which 
were diarrhea, pneumonitis, and elevated liver enzymes. Another observation that was 
noted in this study was that combined therapy with anti-PD-1/PD-L1 mAbs and anti-
CTLA-4 mAbs results in an enhanced anti-tumor effect and improved 2 year survival. 
Table 10 shows some of the results from various clinical trials of PD-1/PD-L1 use in 
targeting melanomas (Homet Moreno et al., 2015). 
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Table 10: Emerging clinical data in anti-PD-1/PD-L1 inhibitors (Homet Moreno et 
al., 2015). 
 
Ipilimumab (YERVOY), a monoclonal antibody that blocks CTLA-4, also shows 
promising results in the treatment of advanced melanoma. A randomized, double-blind, 
phase 2 study in which advanced melanoma patients were assigned a dose of Ipilimumab 
every three weeks for four cycles. Table 11 shows the results. 
 
Table 11: Summary of results of anti-CTLA-4 mAb on advanced melanoma patients 
(Wolchok et al., 2010).  
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All three treatment groups noted stabilization of the disease followed by steady, 
but slow, decline in the total tumor burden. The most frequently noted adverse events 
were immune-related and mainly affected the skin and gastrointestinal tract. However, 
these AEs were noted to be less than 5% in all treatment groups. The data lends support 
to the observation that CTLA-4 target inhibition and lymphocyte activation was enhanced 
at the highest Ipilimumab dose (Wolchok et al., 2010). 
Another study examined the effect of a combined blockade of PD-1 and CTLA-4 
as well as B7 inhibition on B16 melanoma. B16 melanoma cells express either GM-CSF 
(Gvax) or Flt3-ligand (Fvax), which are both tumor specific cell surface proteins. The 
study found that anti-CTLA-4 mAbs alone inhibited growth and proliferation in only 
10% of tumors, while adding anti-PD-1 mAbs increased the efficacy of this 
immunotherapy to 65% in the context of an Fvax vaccination. 
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Figure 26: Survival of mice challenged with B16 melanoma cells and vaccinated on 
days 3, 6, and 9 with (A) Gvax or (B) Fvax (Curran, Montalvo, Yagita, & Allison, 
2010). 
 
The combined therapy also increased the ratios of CD8+ T cells to Treg cells and the 
ratio of CD4+ T effector cells to Treg cells, showing that the tumor microenvironment 
was affected and changed by the therapy. As noted in the Figure 27D and 27E below, the 
blockade of CTLA-4/PD-1 or CTLA-4/PD-1/PD-L1 dramatically increased the 
aforementioned ratios. 
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Figure 27: Lymphocyte infiltration of B16 melanoma. (A) CD45+ to CD8+ T cell 
percentage, (B) CD45+ to CD4+ T effector cells, (C) CD45+ to Treg cells, (D) CD8+ 
T cells to Treg cells, (E) CD4+ T effector cells to Treg cells (Curran et al., 2010). 
 
 
Other notable results included: reduction of Treg activation markers on tumor cells, 
increase in inflammatory cytokine production in the tumor lymph node and tumor itself, 
increase in CTLA-4 and PD-1 expression in tumor-infiltrating lymphocytes (TIL), and 
increase in ratio of T effector cells to MDSCs in the tumor. Overall, it was shown that in 
the context of the Fvax vaccination, combination blockade of CTLA-4 and PD-1 resulted 
in synergistic levels of tumor rejection in B16 melanoma. The accumulation of CTLA-4 
and PD-1 positive T effector cells in this melanoma suggests that the blockade allows T 
cells that would normally be suppressed by the tumor microenvironment to continue 
expanding, proliferating, and carrying out antitumor functions. Alone, these treatments 
had modest effects on the tumors, but simultaneous blockade of the receptors seems to 
not only cause tumor rejection, but also change the tumor microenvironment into 
something suitable for CTLs and T effector cells (Curran et al., 2010, p. -). 
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In melanoma, the use of anti-PD-1 mAbs alone have been shown to have 40% 
objective response rate in antitumor activity. However, this number can be improved, and 
researchers have investigated other modes of delivery to help boost the response rate of 
this immunotherapy. One such mode is a microneedle patch that is applied directly to the 
tumor, in contrast to intravenous injections or oral doses of anti-PD-1. In this case, it was 
found that the microneedle, patch-assisted method of delivery enhanced the treatment of 
melanoma. As a painless therapeutic, it was able to directly delivery the mAbs to the 
tumor and restrict its growth (Wang, Ye, Hochu, Sadeghifar, & GU, 2016). 
Melanoma immunotherapeutics have been shown to rescue patients with advanced or 
metastatic melanoma with little side effects. However, the overall efficacy of 
immunotherapies remains low, perhaps because along with the blockade of coinhibitory 
signals, the tumor microenvironment must be changed from immunosuppressive to 
immunostimulatory. Research continues to pursue combination therapy that release the 
brakes on the patient’s immune system by blocking inhibitory signals and also 
stimulating expression and activation of cytotoxic and effector lymphocytes. 
 
 
What’s the hold up?  
 
One of the greatest concerns with immunotherapy is that “releasing the brakes” on 
the patient’s own immune system may lead to autoimmune disease. As first generation 
immunotherapies focus on blocking specific immune checkpoints such as CTLA-4 and 
PD-1, they also can cause a removal of self-tolerance for normal human cells. Although 
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this development of autoimmune disease can be treated by using steroids that counteract 
lymphocyte activation, this then will compromise tumor response to the mAbs. Table 12 
below shows the relationship between autoimmune disease and specific checkpoint 
inhibitors. 
 
Table 12: The CTLA-4, PD-1, and PD-L1 genes that are linked to self-tolerance and 
involved in autoimmune disease (Michot et al., 2016). 
 
Another problem that exists is the fact that there is no consensus on how a tumor 
should be defined. Pharmaceutical companies use different immunohistochemistry, 
algorithms, and different positivity thresholds to define various cancers that are targets 
for this type of therapy. For this reason, it is important to work closely with cancer 
specialists, who can not only define the patient’s cancer and direct what therapies should 
be used, but also be able to give insights into possible, future autoimmune diseases 
(Michot et al., 2016). 
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CONCLUSIONS AND NEXT STEPS 
 
 
Immunotherapy is one of the next steps being taken in developing targeted therapy. 
Its appeal lies in the fact that it activates the patient’s own immune system that has been 
repressed by the tumor, to target and remove the cancer. It requires an improved 
understanding in antitumor immunity, which is controlled by a delicate balance in the 
tumor microenvironment between the immune stimulatory and immune inhibitory 
pathways. While the blockade of immune checkpoint mechanisms such as CTLA-4 and 
PD-1/PD-L1 continues to be researched, it is also important to focus attention on the 
tumor microenvironment, and how it plays a role in shaping an immunosuppressive, self-
tolerance inducing niche for the tumor. In order to augment and broaden the efficacy of 
these inhibitors, combination therapies have been brought to the forefront of 
investigations. Thus, immunotherapy with some chemotherapy, radiation, or surgery may 
be more effective in preventing proliferation and growth of the tumor and promoting 
tumor rejection (Menon, Shin, & Dy, 2016). 
In the numerous recent discoveries, the utilization of dendritic cells, cancer vaccines, 
antitumor antibodies, adoptive T cell therapy, immune checkpoint blockade, and 
combinations of these therapies with chemotherapy and radiation have resulted in 
unprecedented advancement in targeting and removing cancers that were previously 
thought to be incurable or untreatable (Raval, Sharabi, Walker, Drake, & Sharma, 2014). 
There are still many obstacles to overcome, the main being an autoimmune response, but 
there are important implications in this therapy for the future of personalized medicine. 
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